Segall Bryant & Hamill LLC Has $10.01 Million Position in Glaukos Corporation (NYSE:GKOS)

Segall Bryant & Hamill LLC reduced its position in shares of Glaukos Corporation (NYSE:GKOS - Free Report) by 2.7% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 101,679 shares of the medical instruments supplier's stock after selling 2,870 shares during the quarter. Segall Bryant & Hamill LLC owned about 0.18% of Glaukos worth $10,007,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Victory Capital Management Inc. raised its holdings in Glaukos by 88.7% during the 1st quarter. Victory Capital Management Inc. now owns 140,411 shares of the medical instruments supplier's stock worth $13,819,000 after purchasing an additional 66,009 shares during the last quarter. Xponance Inc. grew its position in shares of Glaukos by 5.8% during the 1st quarter. Xponance Inc. now owns 3,843 shares of the medical instruments supplier's stock worth $378,000 after buying an additional 210 shares during the period. Valeo Financial Advisors LLC grew its position in shares of Glaukos by 1.5% during the 1st quarter. Valeo Financial Advisors LLC now owns 7,817 shares of the medical instruments supplier's stock worth $769,000 after buying an additional 117 shares during the period. Capital Management Associates Inc acquired a new position in shares of Glaukos during the 1st quarter worth about $217,000. Finally, Principal Financial Group Inc. grew its position in shares of Glaukos by 21.8% during the 1st quarter. Principal Financial Group Inc. now owns 327,036 shares of the medical instruments supplier's stock worth $32,187,000 after buying an additional 58,502 shares during the period. 99.04% of the stock is owned by institutional investors.

Glaukos Stock Down 1.3%

NYSE GKOS traded down $1.24 during trading on Friday, hitting $97.76. The stock had a trading volume of 599,069 shares, compared to its average volume of 748,406. The company has a market capitalization of $5.59 billion, a PE ratio of -41.25 and a beta of 0.82. The company's 50-day moving average price is $98.28 and its two-hundred day moving average price is $112.40. The company has a debt-to-equity ratio of 0.09, a quick ratio of 5.62 and a current ratio of 6.49. Glaukos Corporation has a 12 month low of $77.10 and a 12 month high of $163.71.

Glaukos (NYSE:GKOS - Get Free Report) last released its earnings results on Wednesday, April 30th. The medical instruments supplier reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.33) by $0.11. The firm had revenue of $106.66 million for the quarter, compared to analysts' expectations of $102.78 million. Glaukos had a negative return on equity of 10.66% and a negative net margin of 31.40%. The business's quarterly revenue was up 24.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.70) EPS. As a group, sell-side analysts forecast that Glaukos Corporation will post -1.08 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on GKOS. Needham & Company LLC decreased their target price on Glaukos from $176.00 to $115.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Truist Financial restated a "buy" rating and set a $135.00 target price (down from $140.00) on shares of Glaukos in a research report on Thursday, May 1st. BTIG Research restated a "buy" rating on shares of Glaukos in a research report on Monday, July 14th. Morgan Stanley decreased their target price on Glaukos from $110.00 to $72.00 and set an "underweight" rating for the company in a research report on Tuesday, May 6th. Finally, Piper Sandler cut their price objective on Glaukos from $180.00 to $165.00 and set an "overweight" rating on the stock in a report on Tuesday, April 15th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $134.67.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.